A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia

References

• Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology54, S10–S15 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60, 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1154–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Wallin AK, Andreasen N, Eriksson S et al. Donepezil in Alzheimer’s disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord.23, 150–160 (2007).
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer’s disease and vascular dementia. J. Neurol. Sci.229–230, 43–49 (2005).
   PubMed Web of Science ®Google Scholar
• Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J. Am. Geriatr. Soc.53, 1269–1270 (2005).
   PubMed Web of Science ®Google Scholar
• Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis. Assoc. Disord.16, 49–51 (2002).
   PubMed Web of Science ®Google Scholar
• Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: can a transdermal patch offer a solution? Curr. Med. Res. Opin.23, 2705–2713 (2007).
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol.1, S26–S34 (1998).
   Google Scholar
• Doraiswamy PM, Krishnan KR, Anand R et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits? Prog. Neuropsychopharmacol. Biol. Psychiatry26, 705–712 (2002).
   PubMed Web of Science ®Google Scholar
• Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin. Ther.26, 980–990 (2004).
   PubMed Web of Science ®Google Scholar
• Mercier F, Lefèvre G, Huang AH-L, Schmidli H, Amzal B, Appel-Dingmanse S. Rivastigmine exposure provided by a transdermal patch versus capsule. Curr. Med. Res. Opin. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Darreh-Shori T, Almkvist O, Guan ZZ et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology59, 563–572 (2002).
   PubMed Web of Science ®Google Scholar
• Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer’s disease by rivastigmine: correlation with cognitive benefit. J. Neural Transm.109, 1053–1065 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging13, 391–411 (1998).
   PubMed Web of Science ®Google Scholar
• Feldman HH, Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry78(10), 1056–1063 (2007).
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs15, 375–390 (2001).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Sedek G, Huang HL et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol.47, 471–478 (2007).
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry22, 456–467 (2007).
   PubMed Web of Science ®Google Scholar
• Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging23, 357–375 (2006).
   PubMed Web of Science ®Google Scholar
• Cevc G. Drug delivery across the skin. Expert Opin. Investig. Drugs6, 1887–1937 (1997).
   PubMedGoogle Scholar
• Nitti VW, Sanders S, Staskin DR et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology67, 657–664 (2006).
   PubMed Web of Science ®Google Scholar
• Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care20, 1512–1517 (1997).
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Sedek G, Jhee S et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin. Pharm. Ther. DOI:10.1038/sj.clpt.6100242 (2007) (Epub ahead of print).
   PubMedGoogle Scholar